Navigation Links
Independent panel to present findings on diagnosing gestational diabetes mellitus


Gestational diabetes mellitus (GDM) is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy (especially during the third trimester of pregnancy). It is defined as carbohydrate intolerance, which is the inability of the body to adequately process carbohydrates (sugars and starches) into energy for the body, that develops or is first recognized during pregnancy. GDM is estimated to occur in 1 to 14 percent of U.S. pregnancies, affecting more than 200,000 women annually. It is one of the most common disorders in pregnancy and is associated with an increased risk of complications for the mother and child. Potential complications during pregnancy and delivery include preeclampsia (high blood pressure and excess protein in the urine), cesarean delivery, macrosomia (large birth weight), shoulder dystocia (when a baby's shoulders become lodged during delivery), and birth injuries. For the neonate, complications include difficulty breathing at birth, hypoglycemia (low blood sugar), and jaundice. Up to one-half of women who have GDM during pregnancy will develop type 2 diabetes later in life.

Although the U.S. Preventive Services Task Force found in 2008 that the evidence was insufficient to assess the balance between the benefits and harms of screening women for GDM, the American College of Obstetricians and Gynecologists recommends universal screening for gestational diabetes using patient history, risk factors, or laboratory testing, such as with a glucose challenge test (GCT). Different approaches are used internationally for screening and diagnosis of GDM. Debate continues regarding the choice of tests and the effectiveness of treatment, especially in women with mild to moderate glucose intolerance.

To better understand the benefits and risks of various GDM diagnostic approaches, the National Institutes of Health is convening a Consensus Development Conference March 4-6, 2013 to assess the available scientific evidence. An impartial, independent panel will hold a press telebriefing after the conference to discuss their findings and implications for the public. The panel's statement will incorporate their assessment of the available evidence from a systematic literature review, expert presentations, and audience input to inform public and provider decisions regarding diagnosing gestational diabetes mellitus. Additional information about the NIH Consensus Development Conference: Diagnosing Diabetes Mellitus is available at

Who, When & Where:

Members of the Consensus Development Panel, to be announced Monday, March 4, 2013.

Presentation and discussion of the panel's draft statement:

  • Wednesday, March 6, 2013 at 9 a.m. EST
  • Natcher Conference Center on the main NIH campus in Bethesda, Md.
  • Also available via live webcast:

Press Telebriefing: Presentation and discussion of the panel's draft statement:

Please call in 5 to 10 minutes prior to the start of the telebriefing. Media will be asked for name and outlet. Interested parties who are not affiliated with a media outlet may listen in, but will not be permitted to ask questions during the call.

Conference Information: The Consensus Development Conference is free and open to the public. Conference times are listed below and further details are available at

  • Monday, March 4, 2013 - 8:30 a.m. - 5 p.m.
  • Tuesday, March 5, 2013 - 8:30 a.m. - 11 a.m.
  • Wednesday, March 6, 2013 - 9 a.m. - 11 a.m.

Live and archived webcast:


Contact: Deborah Langer
NIH/Office of Disease Prevention

Related medicine news :

1. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
2. Reveals How Project CAP and Insurance Agoragate will Take Away Market Share from the Captive Insurance Carriers and give it back to the Independents
3. A Void In The Independent Pharmacy Industry Leads to Independent Rx Consulting, Powered by OurHelix
4. Helping Alzheimers patients stay independent
5. Independent Care to Open New Office with Service Area Expansion
6. Funding Meals on Wheels Keeps Seniors Independent: Study
7. Study shows COPD is not independent risk factor for lung cancer
8. Omega XL Reports New Independent Study:Omega-3s Help Heal Bedsores In Critically Ill
9. Independent Research Shows That Medrio, a Leading EDC and eClinical SaaS Provider for Clinical Research, Continues to Achieve Exceptional Scores in Customer Satisfaction
10. Yumi Media Encourages Vegetarianism For Heart Health As Reported In the Independent Florida Alligator
11. Liproxenol is First Diet Pill to Earn Perfect Score from Independent Review Organization
Post Your Comments:
(Date:10/13/2015)... ... , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to announce that ... March 2nd and 3rd, 2016. The annual meeting, along with the Dallas Rhinoplasty ... around the world. , Key topics at this year's event will include discussions on ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a ... announced today a significant contract that will provide its award-winning private messaging solution ... on the growing success of its Relay program, IBX Wire™, which now has ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of ... train with, participate in local fitness & sporting events, and stay motivated. ... high medical costs drive us to get more serious about fitness and wellness, individuals ...
(Date:10/13/2015)... Boston, MA (PRWEB) , ... October 13, 2015 , ... ... mortar of the body, including muscle, bone, and blood. But how much protein does ... more complicated than it might seem, according to the October 2015 issue of ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Scientists in ... tissue biopsy in 18 patients with or without mesothelioma. Surviving Mesothelioma has just posted ... , The doctors from PhenoPath Laboratories in Seattle and the University of British Columbia ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  Data Science Automation (DSA), ... opening of a new branch office in the ... DSA,s presence in Europe . The decision ... increasing demand for local support of customers in the medical ... Ph.D., DSA,s UK Branch Manager. "We have had tremendous success ...
(Date:10/13/2015)... -- SeraCare Life Sciences, a leading partner to global in ... medicine business unit has launched its second product in ... (NGS)-based tumor profiling assays.  The Seraseq TM Solid ... mutations in key oncogenes and tumor suppressor genes as ... is offered at five additional allele frequencies. ...
(Date:10/13/2015)... , Oct. 13, 2015  Graduate students across ... and medical research, will soon have the opportunity ... care – the drug discovery and development process. ... has collaborated with 10 leaders from academic institutions ... Medicines: The Process of Drug Development."  Lilly will ...
Breaking Medicine Technology: